ADHS/DBHS (Arizona Department of Health Services, Division of Behavioral Health) (1998). Behavioral Health Services RFP: Data Supplement.
ADHS/DBHS (Arizona Department of Health Services, Division of Behavioral Health) (1999). Behavioral Health Services Checklist for Determination of Serious Mental Illness, Effective 4/15/96.
ADHS (Arizona Department of Health Services) (1998). Department of Health Services: FY 2000 & FY 2001 Preliminary Budget Issue.
AHCPR (Agency for Health Care Policy and Research) (1999) Treatment of Depression-Newer Pharmacotherapies, No. 99-E013.
American Psychiatric Association (1993). "Practice Guidelines for Major Depressive Disorder in Adults," American Journal of Psychiatry 150(4):1-26.
Croghan TW, RL Obenchain, WE Crown (1998). "What does Treatment of Depression Really Cost?" Health Affairs 17(4):198-208.
Department of Health and Human Services, Health Care Financing Administration. Letter to state Medicaid directors dated February 12, 1998.
Druss BG and RA Rosenheck (1997). "Use of Medical Services by Veterans with Mental Disorders," Psychosomatics 38: 451-458.
Frank RG, ER Berndt, SH Busch (1998). "Price Indexes for Treatment of Depression," in Jack E. Triplett, ed., Measuring the Prices of Medical Treatments. Washington DC: Brookings Institution Press.
Gelenberg AJ and SA Mullens (1999). Mind & Medicine: A Monthly Consumer's Guide to Psychiatric Medications 1:2.
Glazer WM (1998). "Atypical Antipsychotics and Formulary Decisions," American Journal of Managed Care 1: Supplement 8-14.
Greenberg PE, RC Kessler, TL Nells et al, 1997. "Depression in the Workplace: An Economic Perspective," in Marcia Byrnes, ed., Medical Cost Offset II. Tiburon, California: CentraLink Publications, No. 2.
Hendrix ML (1999). "Bipolar Disorder," National Institute of Mental Health. www.nimh.nih.gov.
Henk JH, D. Katzelnick, KA Kobak, JH Greist, JW Jefferson (1996). "Medical Costs Attributed to Depression Among Patients with a History of High Medical Expenses In a Health Maintenance Organization," Archives of General Psychiatry 53(10):899-904.
Hylan TR, DP Buesching and GD Tollefson (1998). "Health Economic Evaluations of Antidepressants: A Review," Depression and Anxiety 7:53-64.
IOM (Institute of Medicine) (1997). Managing Managed Care: Quality Improvement in Behavioral Health. Washington, DC. National Academy Press.
IOM (Institute of Medicine) (1996). Primary Care: America's Health in a New Era. Washington, DC. National Academy Press.
Kane JM and SR Marder (1998). "Psychopharmacologic Treatment of Schizophrenia," Schizophrenia Bulletin 19:287-302.
Kane JM (1987). "Treatment of Schizophrenia," Schizophrenia Bulletin 13:133-156.
Kessler RC et. al. (1994). "Lifetime and Twelve-Month Prevalence of SDM-III-R Psychiatric Disorders in the United States: Results from the National Comorbidity Survey," Archives of General Psychiatry 51(1):8-19.
Lindstrom E, B Eriksson, A Hellgren et al. (1995). "Efficacy and Safety of Risperidone in the Long-term Treatment of Patients with Schizophrenia," Clinical Therapy 17:402-412.
Loebel A, SR Botts and BI Feldman (1998). "Atypical Antipsychotics in the Managed Care Era," American Journal of Managed Care 4: Supplement 37-50.
McCollum MA (1997). "Models of Alternative Funding Structures and Cost Effective Care," The Carter Center Fourth Plenary Session: Practical Models for Service Delivery and Cost Effective Long Term Care and Supports for People with Severe Mental Illnesses, November 12, 1997.
Meltzer HY, P Cola L Way et al. (1993). "Cost Effectiveness of Clozapine in Neuroleptic-resistant Schizophrenia," American Journal of Psychiatry 150:1630-1638.
NIMH (National Institute of Mental Health) (1999) Depression Research: Fact Sheet, April. www.nimh.nih.gov
Melfi CA et.al. (1998). "The Effects of Adherence to Antidepressant Treatment Guidelines on Relapse and Recurrence of Depression," Archives of General Psychiatry 55:1128-1132.
McFarlan BH et. al., (1996) "Enrollment Duration, Service Use, and Costs of Care for Severely Mentally Ill Members of a Health Maintenance Organization," Archives of General Psychiatry 53:938-944.
Merrill, R (1999). "Modernizing the FDA: An Incremental Revolution," Health Affairs 12(2):96-111.
Olfson M, M Sing M, HJ Schlesinger (1999). "Mental Health/Medical Care Cost Offsets: Opportunities for Managed Care," Health Affairs 18(2):79-90.
Thomas L (1974). The Lives of a Cell. New York: The Viking Press.
Thompson D et al. (1998). "Predictors of a Medical-Offset Effect Among Patients Receiving Antidepressant Therapy," American Journal of Psychiatry 155:824-827.
Tollefson GD and TM Sanger (1997). "Negative Symptoms: A Path Analytic Approach to a Double-Blind, Placebo- and Haloperidol-Controlled Clinical Trial with Olanzapine," American Journal of Psychiatry 154(4): 466-474.
Value Options: Interview with Dan Weaver (1999).
Viale G, L Mechling, G Maislin et al. "Impact of Risperidone on the Use of Mental Health Resources," Psychiatric Services 48:1153-1159.
Von Korff M, J Ormel, W Katon, and EHB Lin (1992). "Disability and Depression Among High Utilizers of Health Care," Archives of General Psychiatry 49(2):91-100.
Weisbrod BA and L LaMay (1999). "Mixed Signals: Public Policy and the Future of Health Care R&D;," Health Affairs 18(2):112-125.
Weisbrod BA (1991). "The Health Care Quadrilemma: An Essay on Technological Change, Insurance, Quality of Care and Cost Containment," Journal of Economic Literature 29:523-552.
Willis, A. (1999). "Prescription Drugs: Issues of Cost, Coverage, and Quality," ERBI (Employee Research Benefits Institute) Issue Brief No. 208
Wulkan, P.D. (1999). "Pharmacoeconomics of New Generation Medications in a Public Mental Health Setting," Southern Nevada Adult Mental Health Services, Las Vegas, Nevada.